Interferons, serotonin and neurotoxicity

被引:51
作者
Menkes, DB
MacDonald, JA
机构
[1] Dunedin Publ Hosp, Dunedin, New Zealand
[2] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand
关键词
D O I
10.1017/S0033291799001774
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background. Interferons are a class of cytokines profoundly affecting immune function. Several interferons are now synthesized and used clinically, notably for viral diseases and cancer. In addition to their desired immune effects, interferons cause a number of toxicities, including prominent effects on the nervous system. Methods. This literature review focused on the incidence of depression associated with interferon treatment. Possible neurochemical mechanisms and remedial strategies were also considered. Results. Interferon treatment, particularly with the alpha subtype, is unquestionably linked with depression, but the strength of association is uncertain because of erratic ascertainment and pretreatment co-morbidity. A likely pathogenic mechanism has been described, involving interferon suppression of serotonin synthesis. Controlled treatment trials of interferon-induced depression are not yet available. Conclusions. Neurotoxicity substantially limits the use of interferons. At least some of the risk of depression appears to derive from their anti-serotonergic effects, consistent with the large body of evidence pointing to a general link between serotonin and affective illness. Vigilant detection and aggressive treatment of depression is necessary to optimize interferon treatment of many patients.
引用
收藏
页码:259 / 268
页数:10
相关论文
共 111 条
[1]  
ABREU P, 1994, NEUROREPORT, V5, P1356, DOI 10.1097/00001756-199406000-00016
[2]  
Adam Z, 1994, Vnitr Lek, V40, P127
[3]   DECREASED PLASMA TRYPTOPHAN CONCENTRATION IN MAJOR DEPRESSION - RELATIONSHIP TO MELANCHOLIA AND WEIGHT-LOSS [J].
ANDERSON, IM ;
PARRYBILLINGS, M ;
NEWSHOLME, EA ;
POORTMANS, JR ;
COWEN, PJ .
JOURNAL OF AFFECTIVE DISORDERS, 1990, 20 (03) :185-191
[4]   SYMPTOMATIC MYOPATHY ASSOCIATED WITH INTERFERON THERAPY FOR CHRONIC HEPATITIS-C [J].
ARAI, H ;
TANAKA, M ;
OHTA, K ;
KOJO, T ;
NIIJIMA, K ;
IMAWARI, M .
LANCET, 1995, 345 (8949) :582-582
[5]  
ASHCROFT GW, 1966, LANCET, V2, P1049
[6]   Dynamics of ECT normalization of low G protein function and immunoreactivity in mononuclear leukocytes of patients with major depression [J].
Avissar, S ;
Nechamkin, Y ;
Roitman, G ;
Schreiber, G .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (05) :666-671
[7]   TRYPANOSOMA-BRUCEI AND THE NERVOUS-SYSTEM [J].
BENTIVOGLIO, M ;
GRASSIZUCCONI, C ;
OLSSON, T ;
KRISTENSSON, K .
TRENDS IN NEUROSCIENCES, 1994, 17 (08) :325-329
[8]   CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION [J].
BLIER, P ;
DEMONTIGNY, C .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :220-226
[9]   Central injection of IL-10 antagonizes the behavioural effects of lipopolysaccharide in rats [J].
Bluthé, RM ;
Castanon, N ;
Pousset, F ;
Bristow, A ;
Ball, C ;
Lestage, J ;
Michaud, B ;
Kelley, KW ;
Dantzer, R .
PSYCHONEUROENDOCRINOLOGY, 1999, 24 (03) :301-311
[10]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795